TCF Share Price Performance
UK£0.0021
-0.00 (-65.00%)
Price UK£0.0021
Share PriceUK£0.0021
Theracryf Plc Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
TCF Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Theracryf Plc Key Details
About TCF
- Founded
- 2014
- Employees
- 9
- CEO
- WebsiteView website
Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.
